Antiproliferative effects of the CDK6 inhibitor PD0332991 and its effect on signaling networks in gastric cancer cells

PD0332991 (palbociclib/Ibrance(®)) is a cyclin-dependent kinase (CDK)4/6 inhibitor that has recently been approved for the treatment of estrogen receptor-positive advanced breast cancer. The present study investigated the antiproliferative effects of PD0332991 on gastric cancer (GC) cells and the un...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Daguang, Sun, Yabin, Li, Wei, Ye, Fei, Zhang, Yang, Guo, Yuchen, Zhang, David Y., Suo, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846637/
https://www.ncbi.nlm.nih.gov/pubmed/29436583
http://dx.doi.org/10.3892/ijmm.2018.3460

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846637/
https://www.ncbi.nlm.nih.gov/pubmed/29436583
http://dx.doi.org/10.3892/ijmm.2018.3460

Ejemplares similares